I recently did a Q&A interview with NeoStem CEO Dr. Robin Smith. I posted Part 1 of that interview a few days ago here. Now we have part two focused on VSEL, ES cells, and iPS cells. PK: I frequently have readers of my blog ask questions about VSEL. They seem puzzled and unsure of […]
Interview with NeoStem CEO Robin Smith Part 2: VSEL, ES cells, and iPS cells Read More »
I’ve already talked with science writer Ed Yong about the new Nature iPS cell paper Araki, et al. (you can read Ed’s well-written piece here and you can another one on it by another one of my favorite writers, Monya Baker here), which suggests that iPS cells don’t trigger much in the way of an immune
Some thoughts on the Araki Nature iPS cell paper: an advance, but a few key caveats Read More »
Today the Supreme Court announced it would not hear the Sherley v Sebelius case, ending the court battle that has left embryonic stem cell research (ESCR) in what I’ve called a “big chill”. This is great news. It is all over the mainstream media. Even the rampant anti-science, pro-lifers have declared defeat. I’m not going
A great day for stem cell research: more on SCOTUS & details on BioTime news Read More »
In previous years I’ve done yearly predictions for the coming year’s events in the stem cell world (see predictions for 2011 and 2012 predictions). I did pretty well in my predicting stem cell events for this year (see analysis here) scoring a respectable 70%. Isn’t that a C-?,you might ask. No, when it comes to
My stem cell predictions for 2013 Read More »
Advanced Cell Technology (ACT) is well into clinical trials for macular degeneration (the leading cause of blindness) using human embryonic stem cell (hESC)-based retinal pigmented epithelial cells (RPE). To date, the trials suggest the products are safe. Efficacy? We don’t know. I am cautiously hopeful, but it is frustrating to know that most clinical trials
The field of induced pluripotent stem cells (iPSC) has really shaken up science over the last half dozen years reversing our notion that differentiated cells are stuck in that fate, when in reality they are plastic and can “turn back the clock” to become embryonic stem cell-like cells. Now we have an iPSC paper in Nature,
Surprising human mosaicism means not all your cells have the same DNA Read More »
When biotech Geron punted on its embryonic stem cell (ESC) program despite having an ongoing FDA-approved clinical trial for spinal cord injury and tens of millions in loan funding from CIRM, many in the stem cell field were upset to put it mildly. Geron repaid the CIRM loan with interest. At the time, the general
CIRM comment on prospect of BioTime buying Geron stem cell program Read More »
I recently did a text mining of all the article titles for Cell Stem Cell for 2012. The results were very insightful (expressed in a beautiful word cloud) for the journal and what are the top areas of focus of authors publishing there. I just did the same analysis for the journal Stem Cells and
Text mining journal Stem Cells: intriguing comparison to Cell Stem Cell Read More »
Cell Stem Cell was the winner of my 2011 best stem cell journal award (see 2011 awards here, 2012 awards will be announced in early January). As I’ve “complained” in the past, the only thing I wish would be different is they’d publish even more articles per issue or per month! But what exactly does Cell
Text mining Cell Stem Cell: surprising insights into the journal Read More »
The Vatican is still interested in stem cells and after its own debacle with a stem cell meeting planned for 2012 that turned into a scandal for them. For that original 2012 meeting they had wisely invited a full spectrum of stem cell researchers including those working on embryonic stem cells, to have great discussions.
Vatican reboots stem cell meeting for 2013, boots ES cell researchers Read More »